A Study to Evaluate the Pharmacokinetics of VI-0521 in Subjects With Hepatic Impairment

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

This study is designed to determine the effects of a single dose of the study medication in subjects with and without hepatic impairment. 18 to 24 subjects will participate by having multiple blood draws taken to measure the level of study medication in their blood over time.

Key facts

Study ID

NCT00768209

Run by

VIVUS LLC

People needed

18

Starts

2008-10-01

Expected to finish

2009-07-01

Last updated by the study team

2009-12-01

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• A total of 18 to 24 subjects will be studied in 3 groups of 6-8 subjects per group. Group 1 will consist of 6-8 males or females with normal hepatic function, 18 to 65 years of age inclusive. Groups 2-3 will consist of 6-8 males or females per group with varying degree of stable hepatic impairment.

You may not qualify if…

• Any Subject meeting the following criteria must be excluded from the trial:
• Known history of clinically significant arrhythmias.
• Acute illness, especially any infection, within 2 weeks of dosing.
• History or presence of:
• Alcoholism or drug abuse within the past 2 years.
• Hypersensitivity or idiosyncratic reaction to compounds related to the study drug or related compounds.
• Any History of Bipolar disorder or psychosis, history of psychiatric hospitalization, greater than one lifetime episode of major depression.
• Blood donation or significant blood loss within 56 days prior to Day 1.
• Plasma donation within 7 days prior to Day 1.
• Any subject who has participated in a previous clinical trial with VI-0521.
• Any subject who received an investigational drug within 30 days prior to dosing in this study.
• Any history of glaucoma, increased intraocular pressure, or medications to treat increased intraocular pressure.
• Serum creatinine > 1.5 for male subjects, and >1.4 for female subjects.
• History of kidney stones in the last 6 months
• Female subjects, who may be pregnant, or are lactating.
• Use of any drug that is known to have clinical significance in inhibiting or inducing liver enzymes involved in drug metabolism.
• Use of tobacco or nicotine products within last 6 months unless subject is hepatically-impaired.

Where it is running

• Clinical Pharmacology of Miami — Miami, Florida, United States
• Orlando Clinical Research Center — Orlando, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.